KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
CAMBRIDGE, Mass. and EXTON, Pa., Jan. 04, 2017 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) at the Westin St. Francis in San Francisco. Idera’s Chief Executive Officer, Vincent Milano, will present a corporate overview and provide an update on the company’s plans and expectations for 2017.
Live audio webcasts of Idera’s presentation and following Q&A session will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. An archived version will also be available on the Company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 8:00 a.m. Eastern Time on Monday, January 09, 2017.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) [email protected]
